Ascendis Pharma Regains Rights to Metabolic Drug TransCon Semaglutide
Ascendis Pharma (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize its TransCon products in metabolic and cardiovascular diseases after terminating a collaboration with Novo Nordisk A/S (NYSE:NVO). The deal includes the investigational once-monthly TransCon Semaglutide for obesity and type 2 diabetes. Neither company has ongoing financial obligations following termination. The move allows Ascendis to independently pursue development of these programs, potentially increasing its control over commercial economics if successful. However, it also shifts responsibility for funding clinical trials, manufacturing, and regulatory submissions back onto the company. The announcement did not provide a timeline or budget for future developments, leaving uncertainty around execution risks. Investors are weighing whether greater ownership justifies increased development costs. While Ascendis has experience with three approved products using its TransCon platform, no new clinical data on Semaglutide's efficacy was disclosed in the termination announcement.
Topics: Ascendis Pharma metabolic diseases Novo Nordisk obesity TransCon Semaglutide type 2 diabetes